Alpha-galactosidase A (GLA) Mutation Analysis
GLA gene which is located in the long (q) arm of the X chromosome at position 22.1 and encodes for the alpha-galactosidase A enzyme. Glycosidases are an important class of enzymes catalyzing many catabolic processes, including cleaving glycoproteins, glycolipids, and polysaccharides. Alpha-galactosidase A is a lysosomal enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It has an important function in breaking down globotriaosylceramide, a fatty substance stored in various types of cardiac and renal cells. Mutation in the GLA gene may produce abnormal version of the enzyme that is unable to break down globotriaosylceramide resulting in a lysosomal storage disorder termed Fabry Disease. Fabry disease (FD) is inherited as an X-linked disorder. Affected male hemizygotes have < 1% of normal enzyme activity while heterozygous females have higher enzyme levels.
Over 3000 mutations of the GAL gene have been described and most kindreds have specific (private) mutations. The age of onset and clinical features are dependent on the nature of the mutation involved but there are no clear genotypic-phenotypic correlations due to the familial nature of the mutations. Total or partial deficiency of Alpha-galactosidase A results in the progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) in tissues, especially blood vessels, kidneys, and myocardium. It is estimated to be the cause of hypertrophic cardiomyopathy (HCM) in 3% in adult patients with a clinical diagnosis of HCM. Fabry disease patients may have other clinical findings such as angiokeratoma, renal insufficiency, proteinuria, neuropathy, neurovascular damage, anemia and corneal deposits. The cardiac findings include hypertrophy, conduction defects, arrhythmias, coronary artery disease, and aortic annular dilation. Other signs and symptoms of Fabry disease include episodes of pain in hands and feet (acroparethesias), decreased sweating (hypohidrosis), gastrointestinal problems, hearing loss, and tinnitus. Life threatening complications of Fabry Disease include progressive renal damage, heart attack, and stroke.
- Diagnostic confirmation of Fabry disease
- Carrier screening for relatives and those with the family history
- Prenatal carrier screening for those with the family history
- Detected pathogenic variants or mutations confirm diagnosis of Fabry disease
- Mutation may be missense, nonsense, splice-site, partial gene rearrangements, and small and large deletions and insertions.
Negative for mutations analyzed (No mutation or pathogenic variant detected)
Whole blood (EDTA), buccal swabs.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Arq Bras Cardiol. 2019;113: 77–84. [PMID: 31291414]
- Front Genet. 2019;10:60. [PMID: 30853972]
- Arq Bras Cardiol. 2019; 113: 85–86. [PMID: 31411295]
- Eur Heart J Case Rep. 2018; 2: yty133. [PMID: 31020209]
- PLoS Genet. 2013;9: e1003632. [PMID: 23935525]